In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...

Prostate Biopsy Findings. PROSTATE biopsy under local anesthesia showed similar safety and detection outcomes, with better comfort trends for transperineal sampling. A retrospecti ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral ...

- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference ...

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic patient ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to ...

ICIs have transformed NSCLC treatment, but disparities in trial enrollment and efficacy reporting persist, limiting insights into treatment benefits across demographics. A meta-analysis of 21 trials ...

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 ...